Cilostazol Stroke Prevention Study : A Placebo-Controlled Double-Blind Trial for Secondary Prevention of Cerebral Infarction. "CSPS"

Completed

Phase 3 Results

Results

The long-term administration of cilostazol significantly prevented the recurrence of cerebral infarction with a relative reduction of 41.7 percent (P=.0150).